What type of therapies are commonly associated with cutaneous reactions?

EGFR inhibitors and antimetabolites are known to be commonly associated with cutaneous reactions due to their specific mechanisms of action and effects on cellular processes. EGFR inhibitors target the epidermal growth factor receptor, which is involved in cell proliferation and survival. When these therapies block this receptor, they can lead to skin-related side effects such as rash, which is often seen in patients undergoing treatment. Commonly, these rashes manifest on the face, chest, and back and resemble acne.

Similarly, antimetabolites interfere with DNA and RNA synthesis, which can alter skin cell turnover and lead to dermatitis or mucositis, further contributing to cutaneous reactions. These skin changes can be an indicator of the drug's mode of action and are often closely monitored during treatment. Because of these characteristics, therapies in this category are more frequently associated with such side effects compared to other classes of cancer therapies.

While other types of therapies, like hormonal therapies, targeted therapies, and immunotherapies, can also cause skin reactions, they tend to have different side effect profiles and are generally less frequently noted for cutaneous side effects compared to EGFR inhibitors and antimetabolites.